

**In the Specification:**

Please amend the specification as follows. On page 5, please replace the paragraph starting on line 19, continuing through page 6, line 4, with the following paragraph:

**DETAILED DESCRIPTION OF THE INVENTION**

The method of the present invention comprises administration of anti-EDG antibodies in conjunction with administration of chemotherapeutic agents (also referred to herein as anti-tumor agents) wherein the combination has a synergistic anti-tumor effect. The invention should not be construed as limited to use with only the particular anti-EDG antibodies or anti-tumor agents disclosed, but is intended to cover all anti-EDG antibodies and anti-tumor agents. Both monoclonal and polyclonal anti-EDG antibodies may be used. Further, antigen-binding antibody fragments of such antibodies, including F(ab')<sub>2</sub>, Fab', Fab, Fv, single chain Fv, Fd' and Fd fragments and derivatives of single chain Fv, may be used. These antibodies and/or antibody fragments may be used conjugated or unconjugated. Several anti-EDG antibodies are known in the art and may be used according to the method of the present invention. Known anti-EDG antibodies include K4-2C10 (or termed SN6f), D4-2G10 (or termed SN6a), Y4-2F1 (or termed SN6j) and P3-2G8 (or termed SN6k), SN6, SN6b, SN6c, SN6d, SN6e, SN6g, SN6h and SN6i (10, 15, 16, 25). The murine hybridoma cell line Y4-2F1 (expressing the monoclonal antibody alternatively termed Y4-2F1 or SN6j) was deposited in American Type Culture Collection ("ATCC") on August 21, 1996, and is designated as ATCC Deposit No. HB-12171. The ATCC is located at 10801 University Boulevard, Manassas, Virginia, 20110-2209. Further, any anti-tumor agent can be used in this invention. Examples of anti-tumor agents include, but are not limited to, cyclophosphamide (CPA), 5-fluorouracil, paclitaxel, methotrexate, cisplatin and doxorubicin.